Volume 6.29 | Aug 7

Prostate Cell News 6.29 August 7, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Recombinant Disintegrin Domain of Human ADAM9 Inhibits Migration and Invasion of DU145 Prostate Tumor Cells
Researchers investigated the role of the recombinant disintegrin domain of the human ADAM9 (rADAM9D) on the adhesive and mobility properties of DU145 prostate tumor cells. rADAM9D was able to support DU145 cell adhesion, inhibit the migration of DU145 cells, as well as the invasion of this cell line through matrigel in vitro. [Cell Adh Migr] Abstract
Development of Simplified and Defined Cell Culture for hPSCs - Watch Now!
PUBLICATIONS (Ranked by impact factor of the journal)

Dual PI3K/mTOR Inhibitor, XL765 (SAR245409), Shows Superior Effects to Sole PI3K [XL147 (SAR245408)] or mTOR [Rapamycin] Inhibition in Prostate Cancer Cell Models
Scientists compared the in vitro effects of the dual PI3K/mTOR inhibitorn with those observed with the sole PI3K or mTOR inhibition in two non-tumor prostate epithelial cell lines, eight prostate cancer cell lines, and 11 prostate cancer cell derivatives. [Tumor Biol] Abstract

Downregulation of HMGA2 Inhibits Cellular Proliferation and Invasion, Improves Cellular Apoptosis in Prostate Cancer
Researchers explored the expression of high mobility group A2 (HMGA2) in prostate cancer tissues and its correlation to the clinical pathology of prostate cancer, and discussed the role of HMGA2 in the development of prostate cancer. [Tumor Biol] Abstract

Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells
Investigators report that 2 muM withaferin A induced cell death selectively in androgen-insensitive PC-3 and DU-145 prostate adenocarcinoma cells, whereas its toxicity was less severe in androgen-sensitive LNCaP prostate adenocarcinoma cells and normal human fibroblasts. [PLoS One] Full Article

Comparative Metabolomic and Lipidomic Analysis of Phenotype Stratified Prostate Cells
Investigators have identified potentially interesting species of different lipid subclasses including phosphatidylcholines, phosphatidylethanolamines, glycerophosphoinositols and other metabolites that are significantly upregulated in prostate cancer cells derived from distant metastatic sites. [PLoS One] Full Article

miR-345 Suppresses Proliferation, Migration and Invasion by Targeting Smad1 in Human Prostate Cancer
Researchers found that the expression of miR-345 was significantly downregulated in prostate cancer and clinical prostate cancer tissues. Overexpression of miR-345 in prostate cancer cells suppressed proliferation, migration and invasion. [J Cancer Res Clin Oncol] Abstract

miR-503 Suppresses Tumor Cell Proliferation and Metastasis by Directly Targeting RNF31 in Prostate Cancer
The effect of RNF31 on prostate cancer (PCa) progression was studied in vitro and in vivo. Silence of RNF31 suppressed PCa cell proliferation and metastasis in vitro and in vivo. [Biochem Biophys Res Commun] Abstract

Expression and Potential Role of the Peptide Orexin-A in Prostate Cancer
Orexin-A administration to the human androgen-dependent prostate carcinoma cells LNCaP up-regulated OX1 receptor expression resulting in a decrease of cell survival. Nnomolar concentrations of the peptide counteracted the testosterone-induced nuclear translocation of the androgen receptor in the cells: the orexin-A action is prevented by the addition of the OX1 receptor antagonist SB-408124 to the test system. [Biochem Biophys Res Commun] Abstract


Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Investigators assigned men with metastatic, hormone-sensitive prostate cancer to receive either androgen-deprivation therapy (ADT) plus docetaxel or ADT alone. The primary objective was to test the hypothesis that the median overall survival would be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among patients receiving ADT alone. [N Engl J Med] Abstract | Press Release

Cryopreservation Media for Stem Cells - Learn More!
The Insulin-Like Growth Factor (IGF) Axis as an Anticancer Target in Prostate Cancer
The authors provide a summary of preclinical and clinical studies on the insulin-like growth factor axis in prostate cancer including treatment with monoclonal antibodies and tyrosine kinase inhibitors. They also address the role of the IGF axis in the biomarkers setting including IGF-binding proteins and genetic variants. [Cancer Lett] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Advaxis’s ADXS-PSA Awarded Research Grants from the Prostate Cancer Foundation and the Movember Foundation
Advaxis, Inc. announced two research projects involving the company’s Lm Technology immunotherapy candidate ADXS-PSA, which is being developed for prostate cancer, have been selected as 2015 Movember Foundation-PCF Challenge Awards, sponsored by the Movember Foundation and the Prostate Cancer Foundation (PCF). [Advaxis, Inc.] Press Release

CDRD & OICR Team up to Advance Cutting-Edge New Cancer Treatments
Two of Canada’s leading drug research and commercialization centers have announced a call for proposals to help bring new cancer treatments to patients through collaborative technology-development projects from academic investigators across Canada. [Center for Drug Research and Development (CDRD)] Press Release

Newcastle Gets £5 Million to Boost Drug Development
Cancer Research UK’s Drug Discovery Committee has awarded Newcastle University’s Northern Institute of Cancer Research £5 million to bring more cancer drugs to clinical trials. [Cancer Research UK] Press Release

From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW ISCBC 2015: International Stem Cell Biology Conference
October 11-12, 2015
Osaka, Japan

Visit our events page to see a complete list of events in the prostate cell community.
NEW Research Associate – Prostate Cancer (Imperial College London)

Harry Eagle Scholar Awards for Postdoctoral Candidates (Albert Einstein College of Medicine of Yeshiva University)

Research Assistant/Associate – Computational Biologist (University of Glasgow)

Postdoctoral Positions – Cancer Research (Rutgers University)

Postdoctoral Position – Functional Cancer Genomics (Institute of Oncology Research)

Assistant Professor- Urology (University of California, Los Angeles)

Postdoctoral Fellow- Oncology (Oregon Health & Science University)

Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us